Flunoprost is a prostaglandin analog. Flunoprost has been used to treat platelet-activating factor-induced shock and to prolong skin allograft survival in mouse models.

Tilsuprost is an iminoprostacyclin derivative patented by Hoechst A.-G. as stable prostacyclin analog useful cytoprotective agent. In preclinical models, Tilsuprost given just before induction of pancreatitis partly prevented the impairment of mitochondrial oxidative and phosphorylative functions, however, these positive effects were limited in acute pancreatitis preceded by acute ethanol intake.

Remiprostol (also known as SC-46275) is a potent, long-acting gastric antisecretory agent that is not readily available systemically after oral administration. This prostaglandin analog is a very potent and highly selective EP3 receptor agonist with antisecretory and cytoprotective actions. Remiprostol was suggested to be potentially useful in the therapeutic treatment of inflammatory diseases such as peptic ulcer disease (painful sores or ulcers in the stomach or small intestine), ulcerative colitis, Crohn's disease, and autoimmune inflammatory diseases of the central nervous system.

Sepetoprost (also known as ONO-9054), prostaglandin analog was developed as a dual agonist of prostaglandin E3 (EP3) and prostaglandin F (FP) receptors. It is known, that the use of a dual prostaglandin EP3 and prostaglandin F receptor agonists is a novel approach for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Sepetoprost was successfully studied in clinical trials phase II for the treatment of open-angle glaucoma, ocular hypertension, and mild open angle-glaucoma.

Taprenepag isopropyl (also known as PF-04217329) a prodrug of CP-544326 (active acid metabolite), a potent and selective EP(2) receptor agonist. Taprenepag isopropyl was studied in a clinical trials phase II involving patients with primary open angle glaucoma. According to Pfizer’s pipelines in May 2011, the study was discontinued.

Spiriprostil (IBI-P-01028 or R,S-cis-6-(6'-carboxyhexyl)-7-trans-n-hexyl-1,3-diazaspiro-[4-4]-nona n-2,4- dione) is a cytoprotective agent. It is an anti-ulcer agent.

Tiaprost is a synthetic analog of prostaglandin F2α (PGF2α) patented by Hoechst A.-G. as an estrus-synchronizing agent for veterinary medicine. Tiaprost treatment reduced the interval from calving to conception in multiparous cows, but it delayed conception and reduced the conception rate in primiparous cows. Treatment with tiaprost impaired reproductive performance in primiparous cows

Nileprost is a prostacyclin analogue stabilized by introduction of the cyano group at its 5-position. Nileprost is a mixed type PGI2/PGE2 agonist. The development of the prostaglandin analogue nileprost [ZK 34798] for use in peptic ulcers has been discontinued at phase II by Schering AG in Germany.

Rioprostil is a methylprostaglandin E1 analog. Rioprostil inhibits gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. In peptic ulcer cases, it facilitates the healing process and the elimination of pain. Rioprostil can also be used to prevent recurrence of duodenal ulcers. However, its development has been discontinued in 2000.

Delprostenate is a synthetic analogue of PGF2-alpha, which is the naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient. It is a useful synchronizer for the sheep.